Dialog Box

Loading...

GBM AGILE: Information for patients

Below are some frequently asked questions about GBM AGILE. We will update this page on a regular basis as new information comes to hand. If you have been diagnosed with brain cancer and want information about how to get on a clinical trial you should speak to your doctor. More information about clinical trials is available at clinicaltrials.gov

UPDATED DEC 20, 2016

What is Cure Brain Cancer Foundation’s role in GBM AGILE and who is responsible for the trial?

The Foundation has both catalysed and provided seed funding for GBM AGILE. The GBM AGILE executive committee, based mainly in the USA is developing the trial protocol and managing the trial.

How can I get on this trial?

At this stage, in Australia, it is envisaged that there will be sites in Brisbane, Sydney and Melbourne. No further information on specific sites is available at this stage. Information about the trial, including start dates will be listed on the clinical trial registries when the trial enrols.

When will it start enroling?

A number of important regulatory steps must be taken before GBM AGILE opens to patients and once they have been addressed we will provide a further update in early 2017.

Click here for a full update.

How many people will be enrolled on this trial?

The current estimate is that, over time, around 300 Australians will be enrolled within a total of approximately 3000 patients worldwide. 

Will I be eligible?

The protocol is currently still in development so eligibility criteria are yet to be finalised. We can confirm that this trial will only be enrolling GBM patients.

What treatments will be trialed?

The agents that will be assessed through the trial have not yet been determined. They may include immunotherapies, targeted agents and chemotherapies that are identified as promising by the ‘Agent Selection’ sub-committee.

Why is this trial only focused on GBM?

GBM or glioblastoma, a grade IV astrocytoma, is widely recognised to be one of the most common and the most deadly brain tumour in adults with most people surviving fewer than 15 months post-diagnosis.

Will children be eligible to go on the trial?

The protocol is still being developed, but it now looks unlikely that paediatric patients will be able to participate in the early stages of the trial. 

Other clinical trials for GBM patients in Australia